Screener
Quest Diagnostics DGX Non-Controlling Interests
Non-Controlling Interests at other companies
Other financials
Where this comes from
Reported directly by Quest Diagnostics in its filing.
Tagged under the XBRL concept us-gaap:MinorityInterest.
The source filing: Quest Diagnostics’s 10-Q, filed July 23, 2026.
- Filed
- Jul 23, 2026, 4:16 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001022079-26-000070
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Additional paid-in capital | 2,374 | 2,381 |
| Retained earnings | 10,374 | 9,994 |
| Accumulated other comprehensive loss | (62) | (27) |
| Treasury stock, at cost; 52 shares as of both June 30, 2026 and December 31, 2025 | (5,172) | (5,180) |
| Total Quest Diagnostics stockholders’ equity | 7,516 | 7,170 |
| Noncontrolling interests | 303 | 36 |
| Total stockholders’ equity | 7,819 | 7,206 |
| Total liabilities and stockholders’ equity | $16,939 | $16,225 |
Cover / Front Matter
FAQ
- What is Quest Diagnostics's non-controlling interests?
- Quest Diagnostics (DGX) reported non-controlling interests of $303M in Q2 2026.
- How has Quest Diagnostics's non-controlling interests changed year-over-year?
- Quest Diagnostics's non-controlling interests increased by 718.9% year-over-year, from $37M to $303M.
- What is the long-term trend for Quest Diagnostics's non-controlling interests?
- Over 5 years (2020 to 2025), Quest Diagnostics's non-controlling interests has grown at a -6.4% compound annual growth rate (CAGR), from $50M to $36M.
- What does non-controlling interests mean?
- Equity attributable to minority shareholders in subsidiaries not fully owned by the parent — their proportional claim on subsidiary net assets.
Ask your AI about Quest Diagnostics's non-controlling interests.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude